Clinical trials in neurological disorders using AAV vectors: Promises and challenges

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 5, 2004, Pages 482-490

  Mandel, Ronald J ^a   Burger, Corinna ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Aspartoasylase; Canavan's disease; Glutamic acid decarboxylase; L aromatic amino acid decarboxylase; Parkinson's disease

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; ASPARTOACYLASE; GLUTAMATE DECARBOXYLASE; LEVODOPA; NERVE GROWTH FACTOR; PARVOVIRUS VECTOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; BRAIN DISEASE; CANAVAN DISEASE; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG SCREENING; DYSKINESIA; HUMAN; LEUKODYSTROPHY; LYSOSOME STORAGE DISEASE; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NEURONAL CEROID LIPOFUSCINOSIS; NEUROSURGERY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARKINSON DISEASE; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; VIRAL GENE THERAPY; VIRUS RECOMBINANT; WHITE MATTER;

CLINICAL TRIALS; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 6344283047     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. The Genetic Modification Clinical Research Information System: The National Institutes of Health, Bethesda, MD, USA (2004). (http://www.gemcris.od.nih.gov/).
2. Muzyczka N, Berns KI: Parvoviridae; The viruses and their replication. In: Fields Virology. Knipe DM, Howley PM (Eds), Lippincott, Williams and Wilkins, Philadelphia, PA, USA (2001):2327-2360.
3. Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loller S, Fraites TJ Jr, Chiodo VA, Phillipsberg T, Muzyczka N, Hauswirth WW, Flotte TR et al: Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods (2002) 28(2):158-167.
4. Fearnley JM, Lees AJ: Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain (1991 ) 114 5):2283-2301.
5. McGeer PL, Itagaki S, Akiyama H, McGeer EG: Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol (1988) 24(4):574-576.
6. Nutt JG, Holford NHG: The response to levodopa in Parkinson's disease: Imposing pharmacological law and order. Ann Neurol (1996) 39(5):561-573.
7. Krack P, Benazzouz A, Pollak P, Limousin P, Piallat B, Hoffmann D, Xie J, Benabid AL: Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation. Mov Disord (1998) 13(6):907-914.
8. Hornykiewicz O: The mechanisms of action of L-dopa in Parkinson's disease. Life Sci (1994) 15(7):1249-1259.
9. Lloyd KG: CNS compensation to dopamine neuron loss in Parkinson's disease. Adv Exp Med Biol (1977) 90:255-266.
10. Lindvall O: Clinical application of neuronal grafts in Parkinson's disease. J Neurol(1994) 242(1 Suppl 1):S54-S56.
11. Kang UJ, Fisher LJ, Joh TH, O'Malley KL, Gage FH: Regulation of dopamine production by genetically modified primary fibroblasts. J Neurosci (1993) 13(12):5203-5211.
12. Leff SE, Rendahl KG, Spratt SK, Kang UJ, Mandel RJ: In vivo L-dopa production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTP cyclohydrolase I with tyrosina hydroxylase. Exp Neurol(1998) 151 2):249-264.
13. Leff SE, Spratt SKS, Snyder RO, Mandel RJ: Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated virus in an animal model of Parkinson's disease. Neuroscience (1999) 92(1):187-198.
14. Sanchez-Pernaute R, Harvey-White J, Cunningham J, Bankiewicz KS: Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol Ther (2001) 4(4):324-330.
15. Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J, Cunningham J, Budinger TF, Harvey-White J: Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol(2000) 164(1):2-14.
16. Muramatsu S, Ono F, Kodera YNM, Takine N, Tsuchida J, Kawasaki K, Ikeguchi K, Fujimoto K, Tsukada H, Terao K et al: AAV vector-mediated gene delivery of aromatic L-amino acid decarboxylase restored L-dopa efficacy in a primate bilateral model of Parkinson's disease. Mol Ther (2004): in press.
17. Chase TN: Levodopa therapy: Consequences of the nonphysiologic replacement of dopamine. Neurology (1998) 50 5 Suppl 5):S17-S25.
18. Krack P, Limousin P, Benabid AL, Pollak P: Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease. Lancet (1997) 350(9092):1676.
19. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, Perret JE, Benabid AL: Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet (1995) 345(8942):91-95.
20. Pollak P, Benabid AL, Gross C, Gao DM, Laurent A, Benazzouz A, Hoffmann D, Gentil M, Perret J: Effects of the stimulation of the subthalamic nucleus in Parkinson disease. Rev Neurol (1993) 149(3):175-176.
21. Crossman AR: Functional anatomy of movement disorders. J Anat (2000) 196(4):519-525.
22. Deep-Brain Stimulation for Parkinson's Disease Study Group: Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med (2001) 345(13):956-963.
23. Benazzouz A, Piallat B, Ni ZG, Koudsie A, Pollak P, Benabid AL: Implication of the subthalamic nucleus in the pathophysiology and pathogenesis of Parkinson'a disease. Cell Transplant (2000) 9 2):215-221.
24. Wichmann T, Bergman H, DeLong MR: The primate subthalamic nucleus. I. Functional properties in intact animals. J Neurophysiol (1994) 72(2):494-506.
25. Wichmann T, Bergman H, DeLong MR: The primate subthalamic nucleus. III Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. J Neurophysiol (1994) 72(2 ):521-530.
26. Bergman H, Wichmann T, Karmon B, DeLong MR: The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol (1994) 72(2):507-520.
27. Wichmann T, DeLong MR: Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol (1996) 6 6):751-758.
28. Benazzouz A, Hallett M: Mechanism of action of deep brain stimulation. Neurology(200O) 55(12 Suppl 6):S13-S16.
29. Luo J, Kaplitt MG, Fitzsimons HL, Zuzga DS, Liu Y, Oshinsky ML, During MJ: Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science (2002) 298(5592):425-429.
30. During MJ, Kaplitt MG, Stern MB, Eidelberg D: Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther (2001) 12 12):1589-1591.
31. Bergman H, Wichmann T, DeLong MR: Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science (1990) 249(4975):1436-1438.
32. Carvalho GA, Nikkhah G: Subthalamic nucleus lesions are neuroprotective against terminal 6-OHDA-induced striatal lesions and restore postural balancing reactions. Exp Neurol (2001) 171 2):405-417.
33. Matalon R, Michals K, Sebesta D, Deanching M, Gashkoff P, Casanova J: Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Meal Genet (1988) 29 2):463-471.
34. Matalon R, Michals-Matalen K: Biochemistry and molecular biology of Canavan disease. Neurochem Res (1999) 24 4):507-513.
35. Matalon R, Rady PL, Platt KA, Skinner HB, Quast M J, Campbell GA, Matalon K, Ceci JD, Tyring SK, Nehls M, Surendran S et al: Knock-out mouse for Canavan disease: A model for gene transfer to the central nervous system. J Gene Med (2000) 2(3): 165-175.
36. Matalon R, Surendran S, Rady PL, Quast MJ, Campbell GA, Matalon KM, Tyring SK, Wei J, Peden CS, Ezell EL, Muzyczka N, Mandel RJ: Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for Canavan disease. Mol Ther (2003) 7(5 Pt 1):580-587.
37. Klein RL, Meyer EM, Peel AL, Zolotukhin S, Meyers C, Muzyczka N, King MA: Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp Neurol (1998) 150(2):183-194.
38. Mandel RJ, Rendahl KG, Spratt SK, Snyder RO, Cohen LK, Left SE: Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydroxylase I in a rat model of Parkinson's disease. J Neurosci (1998) 18(11):4271-4284.
39. Bartlett JS, Samulski RJ, McCown TJ: Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther (1998) 9(8):1181-1186.
40. Leone P, Janson CG, Bilaniuk L, Wang Z, Sorgi F, Huang L, Matalon R, Kaul R, Zeng Z, Freese A, McPhee SW et al: Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann Neurol (2000) 48(1):27-38.
41. Janson C, McPhee S, Bilaniuk L, Haselgrove J, Testaiuti M, Freese A, Wang DJ, Shera D, Hurh P, Rupin J, Saslow E et al: Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther (2002) 13(11):1391-1412.
42. Masliah E, Terry RD, DeTerasa RM, Hansen LA: Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci Lett (1989) 103 2):234-239.
43. Bartus RT, Dean RL 3rd, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science (1982) 217(4558):408-414.
44. Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M: Cholinesterase inhibition for Alzheimer disease: A meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. J Am Med Assoc (1998) 280(20):1777-1782.
45. Levi-Montalcini R, Hamburger V: Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool(1951) 116 2):321-361.
46. Gnahn H, Hefti F, Heumann R, Schwab ME, Thoenen H: NGF-mediated increase of choline acetyltransferase (ChAT) in the neonatal rat forebrain: Evidence for a physiological role of NGF in the brain. DevBrain Res (1983) 9(1):45-52
47. Hefti F: Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci (1986) 6(8):2155-2162.
48. Kromer LF: Nerve growth factor treatment after brain injury prevents neuronal death. Science (1987) 235 4785):214-216
49. Williams LR, Varon S, Peterson GM, Wictorin K, Fischer W, Björklund A, Gage FH: Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci USA (1986) 83(23 ):9231-9235
50. Fischer W, Wictorin K, Björklund A, Williams LR, Varon S, Gage FH: Amelioration of cholinergic neurons atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature (1987) 329(6134):65-68.
51. Fischer W, Björklund A, Chen K, Gage FH: NGF improves spatial memory in aged rodents as a function of age. J Neurosci (1991) 11(7):1889-1906.
52. Mandel RJ, Gage FH, Thai LJ: Spatial learning in rats: Correlation with cortical choline acetyltransferase and improvement with NGF treatment following NBM damage. Exp Neurol (1989) 104(3):268-217.
53. Dekker AJ, Gage FH, Thai LJ: Delayed treatment with nerve growth factor improves acquisition of a spatial task in rats with lesions of the nucleus basalis magnocellularis: Evaluation of the involvement of different neurotransmitter systems. Neuroscience (1992) 48(1):111-119.
54. Tuszynski MH: Growth-factor gone therapy for neurodegenerative disorders. Lancet Neurol (2002) 1 1):51-57.
55. Bjerre B, Björklund A, Stenevi U: Stimulation of growth of new axonal sprouts from lesioned monoamine neurones in adult rat brain by nerve growth factor. Brain Res (1973) 60(1): 161-176.
56. Winkler J, Ramirez GA, Kuhn HG, Peterson DA, Day-Lollini PA, Stewart GR, Tuszynski MH, Gage FH, Thai LJ: Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Ann Neurol (1997) 41(1):82-93.
57. Isaacson LG, Billieu SC: Increased perivascular norepinephrine following intracerebroventricular infusion of NGF into adult rats. Exp Neurol (1996) 139(1):54-60.
58. Emmett CJ, Stewart GR, Johnson RM, Aswani SP, Chan RL, Jakeman LB: Distribution of radioiodinated recombinant human nerve growth factor in primate brain following intracerebroventricular infusion. Exp Neurol (1996) 140(2):151-160.
59. Williams LR: Hypophagia is induced by intracerebroventricular administration of nerve growth factor. Exp Neurol (1991) 113(1):31-37.
60. Seiger Å, Nordberg A, Von Holst H, Backman L, Ebendal T, Alafuzoff I, Amberla K, Hartvig P, Herlitz A, Lilja A et al: Intracranial infusion of purified nerve growth factor to an Alzheimer patient: The first attempt of a possible future treatment strategy. Behav Brain Res (1993) 57(2):255-261.
61. Eriksdotter Jonhagen M, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, Olson L, Seiger A, Shigeta M, Theodorsson E, Viitanen M et al: Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dementia Geriatr Cognitive Disord (1998) 9(5):246-257.
62. Venero JL, Hefti F, Knusel B: Trophic effect of exogenous nerve growth factor on rat striatal cholinergic neurons: Comparison between intraparenchymal and intraventricular administration. Mol Pharmacol (1996) 49(2):303-310.
63. Rosenberg MB, Friedmann T, Robertson RC, Tuszynski M, Wolff JA, Breakefield XO, Gage FH: Grafting genetically modified cells to the damaged brain: Restorative effects of NGF expression. Science (1988) 242(4885):1575-1578
64. Tuszynski MH, Senut MC, Ray J, Roberts J: Somatic gone transfer to the adult primate central nervous system: In vitro and in vivo charaterization of cells genetically modified to secrete nerve growth factor. Neurobiol Dis (1994) 1 1-2):67-78.
65. Tuszynski MH, Roberts J, Senut MC, U HS, Gage FH: Gene therapy in the adult primate brain: Intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Ther (1996) 3 4):305-314.
66. Tuszynski M, Thai L, Pay MM, U HS, Bakay R, Alksne J, Salmon G, Ho G, Tong G, Blesch A et al: A phase I trial of nerve growth factor ex vivo gone therapy for Alzheimer's disease. Neurology (2004) 62(Suppl 5):Abs S17.002.
67. Mandel RJ, Gage FH, Clevenger DG, Spratt SK, Snyder RO, Leff SE: Nerve growth factor expressed in the medial septum following in vivo gene delivery using a recombinant adeno-associated viral vector protects cholinergic neurons from fimbria-fornix lesion-induced degeneration. Exp Neurol(1999) 155(1):59-64
68. Klein RL, Hirko AC, Meyers CA, Grimes JR, Muzyczka N, Meyer EM: NGF gone transfer to intrinsic basal forebrain neurons increases choUnergic cell size and protects from age-related, spatial memory deficits in middle-aged rats. Brain Res (2000) 875 1-2):144-151.
69. Bishop KM, Hofer K, Ruis D, Mehta A, Lawandry S, Brown L, Kruegel B, Tuszynski M, Bartus R: CERE-110, an AAV2-based vector to deliver NGF, provides trophic activity to basal forebrain cholinergic neurons in rats and cynomolgous monkeys. Mol Ther (2004) 9(Suppl 1):S199-S200.
70. Hu L, Wong TP, Cote SL, Bell KF, Cuello AC: The impact of Aβ-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in Alzheimer's disease-like transgenic mice. Neuroscience (2003) 121(2):421-432.
71. Wong TP, Debeir T, Duff K, Cuello AC: Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J Neurosci (1999) 19(7):2706-2716.
72. Mesulam M: The cholinergic lesion of Alzheimer's disease: Pivotal factor or side show? Learn Mem (2004) 11 (1):43-49.
73. Selkoe D, Kopan R: Notch and Presenilin: Regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci (2003) 26:565-597.
74. High K, Manno C, Sabatino D, Hutchinson S, Dake M, Razavi M, Kaye R, Aruda V, Herzog R, Rustagi P et al: Immune responses to AAV and to Factor IX in a phase I study of AAV-mediated liver-directed gone transfer for hemophilia B. Mol Ther (2004) 9(Suppl 1):S383-S384.
75. Peden CS, Burger C, Muzyczka N, Mandel RJ: Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit rAAV2-mediated, but not rAAV5-mediated gone transfer in the brain. J Virol (2004) 78(12):6344-6359.
76. Sanftner LM, Suzuki BM, Doroudchi MM, Feng L, McClelland A, Forsayeth JR, Cunningham J: Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. Mol Ther (2004) 9 3):403-409